Published in Pediatr Hematol Oncol on January 13, 1992
The RNA-binding protein HuR promotes cell migration and cell invasion by stabilizing the beta-actin mRNA in a U-rich-element-dependent manner. Mol Cell Biol (2007) 1.54
Fosfomycin--friend or foe? Pediatr Hematol Oncol (1992) 0.75
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol (1999) 2.25
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia (2000) 2.21
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11
In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood (1995) 2.00
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood (2000) 1.93
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res (2001) 1.75
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol (1995) 1.72
Occurrence of acute nonlymphoblastic leukemia in two girls after treatment of recurrent, disseminated Langerhans cell histiocytosis. Pediatr Hematol Oncol (1999) 1.67
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia (2005) 1.60
CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer (2002) 1.59
Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol (1993) 1.57
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol (1996) 1.55
Interleukin-12 inhibits apoptosis in chronic lymphatic leukemia (CLL) B cells. Cancer Biother Radiopharm (2002) 1.55
Impact of whole-body MRI and FDG-PET on staging and assessment of therapy response in a patient with Ewing sarcoma. Pediatr Blood Cancer (2006) 1.51
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet (1994) 1.43
TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Berlin-Frankfurt-Münster Study Group. Leukemia (1999) 1.40
Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-alpha. Lancet (1993) 1.40
Basic methods and the developing structure of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. For the German Late Effects Study Group in the German Society Pediatric Oncology and Hematology (GPOH). Med Pediatr Oncol (2000) 1.40
Low-grade non-Hodgkin's lymphoma after high-grade non-Hodgkin's lymphoma in a child with ataxia telangiectasia. Cancer (1994) 1.40
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia (2013) 1.39
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia (2010) 1.29
In vivo description of dendritic cells in human renal cell carcinoma. J Urol (1999) 1.23
[Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. Klin Padiatr (1987) 1.23
Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet (2001) 1.21
[The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)]. Klin Padiatr (1981) 1.17
Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia (2001) 1.16
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. J Clin Oncol (2001) 1.15
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol (2001) 1.13
Advantages of a new Taq DNA polymerase in multiplex PCR and time-release PCR. Biotechniques (1998) 1.10
Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia (2012) 1.10
Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus (1990) 1.09
[Biomechanics of the external fixation clamps]. Unfallheilkunde (1978) 1.08
Having children after surviving cancer in childhood or adolescence - results of a Berlin survey. Klin Padiatr (2008) 1.07
Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. Clin Chem (2001) 1.06
Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol (2000) 1.04
Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer (2005) 1.04
Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett (2003) 1.04
Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer (1999) 1.03
Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood (1992) 1.02
Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia (2004) 1.01
Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol (2000) 1.00
Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol (1999) 1.00
Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia (2000) 1.00
Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother (1994) 0.99
Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood (1985) 0.99
Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer (2003) 0.98
Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood (1997) 0.98
Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol (1998) 0.97
Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer (1999) 0.97
Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol (2000) 0.96
Acupuncture to alleviate chemotherapy-induced nausea and vomiting in pediatric oncology - a randomized multicenter crossover pilot trial. Klin Padiatr (2008) 0.95
Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer (1998) 0.95
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother (1993) 0.95
Preliminary results of primary chemotherapy in retinoblastoma. Klin Padiatr (1997) 0.95
Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology (1994) 0.94
Conformational polymorphisms of cRNA of T-cell-receptor genes as a clone-specific molecular marker for cutaneous lymphoma. J Invest Dermatol (1993) 0.94
Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer (1997) 0.94
Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol (1998) 0.92
An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer (2006) 0.91
HBcAg expressed on the surface of circulating Dane particles in patients with hepatitis B virus infection without evidence of anti-HBc formation. Hepatology (1989) 0.91
Definition of a standard-risk group in children with AML. Br J Haematol (1999) 0.89
A transformation-associated 130-kD cell surface glycoprotein is growth controlled in normal human cells. J Exp Med (1988) 0.89
Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma--results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol (2010) 0.89
Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study. J Cancer Res Clin Oncol (1983) 0.89
Successful treatment of pulmonary and cerebral aspergillosis in an immunosuppressed child. Eur J Pediatr (1982) 0.88
Evaluation of a new recommendation for improved cuffed tracheal tube size selection in infants and small children. Acta Anaesthesiol Scand (2006) 0.88
Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia. Blood (2000) 0.88
Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors. J Clin Oncol (1999) 0.87
TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Münster Study Group. Blood (1998) 0.87
Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer (2000) 0.87
Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin Padiatr (2013) 0.86
Hormone and Sperm Analyses after Chemo- and Radiotherapy in Childhood and Adolescence. Klin Padiatr (2010) 0.86
Acute lymphoblastic leukemia: current status of therapy in children. Recent Results Cancer Res (1984) 0.86
Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative? Bone Marrow Transplant (1997) 0.86
Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2000) 0.86
Anterior abdominal wall malignant peripheral nerve sheath tumor in an infant. J Pediatr Surg (2001) 0.86
Sliding appendiceal inguinal hernia with a congenital fibrovascular band connecting the appendix vermiformis to the right testis. Hernia (2001) 0.85
A new development of triterpene acid-containing extracts from Viscum album L. displays synergistic induction of apoptosis in acute lymphoblastic leukaemia. Cell Prolif (2012) 0.85
Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses. Cancer Biother Radiopharm (1997) 0.84
Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing. Oncology (1988) 0.84
Calla-positive acute leukaemia with t(5q;14q) translocation and hypereosinophilia--a unique entity? Acta Haematol (1989) 0.84
Positional stability of sources during low-dose-rate brachytherapy for cervical carcinoma. Int J Radiat Oncol Biol Phys (1993) 0.84
Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr (1998) 0.84
Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo. Acta Haematol (1993) 0.84
Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. Leukemia (2011) 0.84
Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia (2008) 0.84
[Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81]. Klin Padiatr (1987) 0.84
A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol (2012) 0.84